Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases.

NCT04189055

PHASE2INTERVENTIONAL

Hôpital Franco-Britannique-Fondation Cognacq-Jay

72 participants

Started 2020-01-07 · Completed 2024-07

Status: Unknown (as of 12-23-2025)

Conditions

Cancer Colorectal

Interventions

DRUG: Cetuximab DRUG: Irinotecan

Linked Papers (from SciSciNet-V2)

Total Papers9

Background

0

Result

0

Derived

0

Unknown

9

View on ClinicalTrials.gov

Total Citations Per Year

Brief Summary

The purpose of this study is to investigate the efficacy of cetuximab or cetuximab-irinotecan in patients with neo wild-type colorectal cancer who have been previously treated for metastatic disease. Patients will be included in cohort #1 or cohort #2. The inclusion in cohort #2 will start when the results of the cohort #1 are available. Patient will receive either cetuximab alone (cohort #1) or cetuximab with irinotecan (cohort #2).

Sort by:

Background Papers0

No background papers linked

Result Papers0

No result papers linked

Derived Papers0

No derived papers linked

Unknown Papers9

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

74,955 citations

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

4,992 citations

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

3,476 citations

Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

3,101 citations

Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer

Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial

Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil

Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study